Evidence map›Paper›PMID 31790472›Full record

ArticlePloS one2019

A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus.

Yupeng Li, Richard E Higgs, Robert W Hoffman, Ernst R Dow, Xiong Liu, Michelle Petri, Daniel J Wallace, Thomas Dörner, Brian J Eastwood, Bradley B Miller and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Spotlight onGenes · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Yupeng LiEli Lilly and Company, Indianapolis, Indiana, United States of America.ORCID 0000-0003-0843-7592
Richard E HiggsEli Lilly and Company, Indianapolis, Indiana, United States of America.
Robert W HoffmanEli Lilly and Company, Indianapolis, Indiana, United States of America.
Ernst R DowEli Lilly and Company, Indianapolis, Indiana, United States of America.
Xiong LiuEli Lilly and Company, Indianapolis, Indiana, United States of America.
Michelle PetriHopkins Lupus Center, John Hopkins University, Baltimore, Maryland, United States of America.
Daniel J WallaceDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Thomas DörnerCharité University Hospitals, Berlin, Germany.
Brian J EastwoodEli Lilly and Company, Indianapolis, Indiana, United States of America.
Bradley B MillerEli Lilly and Company, Indianapolis, Indiana, United States of America.
Yushi LiuEli Lilly and Company, Indianapolis, Indiana, United States of America.ORCID 0000-0003-4185-4187
Eli Lilly (United States) · USCharité - Universitätsmedizin Berlin · DEJohns Hopkins University · USUniversity of California, Los Angeles · US

Funding

Hopkins Lupus CohortR01AR069572 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2016 to 2020
$3.4M
NIAMS NIH HHS R01 AR069572
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a chronic, remitting, and relapsing, inflammatory disease involving multiple organs, which exhibits abnormalities of both the innate and adaptive immune responses. A limited number of transcriptomic studies have characterized the gene pathways involved in SLE in an attempt to identify the key pathogenic drivers of the disease. In order to further advance our understanding of the pathogenesis of SLE, we used a novel Bayesian network algorithm to hybridize knowledge- and data-driven methods, and then applied the algorithm to build an SLE gene network using transcriptomic data from 1,760 SLE patients' RNA from the two tabalumab Phase III trials (ILLUMINATE-I & -II), the largest SLE RNA dataset to date. Further, based on the gene network, we carried out hub- and key driver-gene analyses for gene prioritization. Our analyses identified that the JAK-STAT pathway genes, including JAK2, STAT1, and STAT2, played essential roles in SLE pathogenesis, and reaffirmed the recent discovery of pathogenic relevance of JAK-STAT signaling in SLE. Additionally, we showed that other genes, such as IRF1, IRF7, PDIA4, FAM72C, TNFSF10, DHX58, SIGLEC1, and PML, may be also important in SLE and serve as potential therapeutic targets for SLE. In summary, using a hybridized network construction approach, we systematically investigated gene-gene interactions based on their transcriptomic profiles, prioritized genes based on their importance in the network structure, and revealed new insights into SLE activity.

Indexed as

Models, GeneticAlgorithmsBayes TheoremClinical Trials, Phase III as TopicComputer SimulationData MiningDatasets as TopicGene Expression ProfilingGene Regulatory NetworksHumansJanus Kinase 2Linear ModelsLupus Erythematosus, SystemicOligonucleotide Array Sequence AnalysisRandomized Controlled Trials as TopicSignal TransductionJAK2 protein, humanJanus Kinase 2STAT1 protein, humanSTAT1 Transcription FactorSTAT2 protein, humanSTAT2 Transcription Factor

Identifiers

PMID31790472
PMCPMC6886858
OpenAlexW2993514836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.